As has been stated, conventional adjuvant chemotherapy with Tmab results in a significant prolongation of disease-free and overall survival rates and has revolutionized the treatment of HER2+ breast cancer [89,90]. This evidence concerns the gene ERBB2 and breast carcinoma.